Since its establishment in 1717, ONO has resolutely pushed forward in the pharmaceutical industry under the corporate philosophy "Dedicated to Man's Fight against Disease and Pain." We aim to contribute to society by developing pharmaceutical products that truly benefits patients, and we will continue to tackle diseases that have not been overcome, as well as the disease areas where the satisfaction level with the treatment is still low among patients and medical needs are high.
As a company that delivers pharmaceutical products affecting the lives and quality of life of patients, we always engage with the community with a sincere and faithful attitude and making efforts to further strengthen our compliance system on a company-wide scale, so as not only to comply with laws and regulations but also to act in accordance with high ethical standards.
As our company continues to grow toward the achievement of global specialty pharma, it goes without saying that we must pursue innovative drug discovery efforts. At the same time it is also necessary to continually strengthen our efforts with respect to the environment, society and corporate governance. We set the ONO PHARMACEUTICAL Codes of Conduct as the basis of our CSR management, and center our activities around materialities (priority CSR issues). By implementing PDCA cycles for each materiality, we move forward with CSR activities that each stakeholder expects us to have, including environmental, social and corporate governance. In doing so, I believe that we can thereby achieve sustainable development for both our company and society. I also promise that we will contribute to the achievement of our 2030 Sustainable Development Goals (SDGs).